With the grant of additional patents in the USA (US1249744) and Japan (JP7791867), mAbsolve’s patent coverage has been further extended to include nucleic acids and Fc fusion proteins which incorporate the STR technology.
These divisional patents build on our existing granted patents in the United States, Japan, United Kingdom, Canada and Australia, which cover antibodies incorporating the STR silencing mutations. The broader scope of these new grants reflects the growing range of applications for our technology beyond conventional antibodies.